Jennifer Michaelson - 05 Nov 2026 Form 4 Insider Report for Cullinan Therapeutics, Inc. (CGEM)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
06 Nov 2026, 17:00:04 UTC
Prior SEC filing
10 Sep 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Filing notes and source

Key filing fact

Jennifer Michaelson filed Form 4 for Cullinan Therapeutics, Inc. (CGEM) on 06 Nov 2026.

Key facts

  • This page summarizes Jennifer Michaelson's Form 4 filing for Cullinan Therapeutics, Inc. (CGEM).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 06 Nov 2026, 17:00.

Change

  • Previous filing in this sequence was filed on 10 Sep 2026.
  • Current net transaction value: -$49,440.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001838061 Primary reporting owner

Michaelson Jennifer

Relationship
Chief Scientific Officer
Address
C/O CULLINAN THERAPEUTICS, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE
Signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Signature date
06 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CGEM transaction

Common Stock

Options Exercise

Transaction value
Shares
+3,805
Change %
+2.4%
Price
$4.30*
Shares after
162,649
Date
05 Nov 2026
Ownership
Direct
CGEM transaction

Common Stock

Sale

Transaction value
-$49,440
Shares
-4,000
Change %
-2.5%
Price
$12.36
Shares after
158,649
Date
05 Nov 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CGEM transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-3,805
Change %
-4.8%
Price
$0.000000*
Shares after
75,182
Date
05 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,805
Exercise price
$4.30
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.

Footnote F2

25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .